This document reports the pooled estimates from the ECDC study of COVID-19 vaccine effectiveness, conducted through the implementation of a multi-country approach using the 'Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory confirmed with SARS-CoV-2, version 1.0'. This second update contains vaccine effectiveness results among individuals aged 30 years and older, for the pre-Delta and the Delta-dominant periods (3 January–31 May 2021 and 1 July–15 December 2021, respectively). It also contains estimates by COVID-19 vaccine product (i.e. Comirnaty and Vaxzevria). Compared with the previous report, two additional countries submitted data retrospectively (Ireland and the Netherlands); therefore, estimates for the pre-Delta period may differ slightly from those published previously.
|Place of Publication||Stockholm|
|Publisher||European Centre for Disease Prevention and Control (ECDC)|
|Number of pages||19|
|Publication status||Published - 14 Mar 2022|
- public health report